Novo Nordisk warns consumers about counterfeit Ozempic® (semaglutide) injection 1 mg in the US

News provided by

Apr 14, 2025, 10:56 ET

Seized counterfeit Ozempic^® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain
Visual examination of seized product contains counterfeit features; product composition has not been conclusively determined at this time
US Food and Drug Administration (FDA) seized counterfeit Ozempic^® and Novo Nordisk is assisting with the investigation

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic^® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug Administration (FDA) has also updated its website with information about these counterfeit versions of Ozempic.

Box image featuring the serial and lot number of counterfeit Ozempic® product

The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517 (illustrated above). Lot number PAR0362 is an authentic lot number. Only when both the lot number is coupled with the eight digits 51746517, it is counterfeit and should not be used.

As the investigation continues, further analyses, including extensive visual examination and chemical testing of the seized, counterfeit product is underway. Accordingly, neither Novo Nordisk nor FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product.

WHAT TO DO: GUIDANCE FOR RETAILERS AND CONSUMERS
Retail pharmacies are advised to purchase authentic Ozempic^® (semaglutide) injection 1 mg and other semaglutide-containing medicines through authorized distributors of Novo Nordisk. Pharmacies are encouraged to review the photographs and information provided above. If there are any concerns about whether your batches are authentic, please call Novo Nordisk customer care at 1-800-727-6500 Monday through Friday from 8:30 AM to 6:00 PM EST.

Patients should double-check their Ozempic^® box to see if it has the lot number PAR0362, and serial number beginning with the first eight digits, 51746517. These products are deemed counterfeit and should not be used. It is important to note that lot number PAR0362 is an authentic lot number. It is counterfeit product only when that lot number has those eight digits in the serial number.

Patients are encouraged to only acquire authentic Novo Nordisk Ozempic^® (semaglutide) injection 1 mg through pharmacies and to check the product for any signs of counterfeiting before using.

If a prescription is filled via a legitimate retailer who uses our authorized distributors, Novo Nordisk believes the risk of receiving counterfeit medicine is minimized. Patients should check the batch number of the product as described above and below.
If you are in possession of a counterfeit product, you are highly encouraged to:
- Report suspicious Ozempic^® product with serial number beginning with the first eight digits, 51746517 or other suspected Novo Nordisk counterfeit products, or if patients need additional help determining if a Novo Nordisk product is counterfeit, please call Novo Nordisk customer care at 1-800-727-6500 Monday through Friday from 8:30 AM to 6:00 PM EST.
- Report it directly with FDA here: Report Suspected Criminal Activity (fda.gov).
- Report any side effect to FDA's MedWatch Safety Information and Adverse Event Reporting Program (1-800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, using the same customer care number (1-800-727-6500).

Websites selling counterfeit and/or tampered medicines should be reported to FDA. Suspected counterfeit products may be reported to FDA by calling your local FDA consumer complaint coordinator or by reporting it directly here Report Suspected Criminal Activity (fda.gov).

Learn more about the responsible use of semaglutide-containing medicines, how to spot counterfeit products and the significant safety and health risks associated with compounded or knock-off "semaglutide" at www.semaglutide.com.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

Contacts for further information

Media:
Liz Skrbkova (US) +1 609 917 0632 [email protected]	Ambre James-Brown (Global) +45 3079 9289 [email protected]
Investors:
Frederik Taylor Pitter (US) +1 609 613 0568 [email protected]	Jacob Martin Wiborg Rode (Global) +45 3075 5956 [email protected]
Sina Meyer (Global) +45 3079 6656 [email protected]	Ida Schaap Melvold (Global) +45 3077 5649 [email protected]
Max Ung (Global) +45 3077 6414 [email protected]